Seeking Alpha
06 Aug 2026, 05:41 UTC · 7w ago
Verdict
Headline takes no side. We score PACB −0.90 across three claims — strongly bearish.
−0.90strongly bearish
More negative than 90% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pacific Biosciences lowered its 2026 revenue guidance to levels below market consensus.
So whatDownwards revisions to long-term growth targets typically trigger significant valuation resets in growth-oriented biotech stocks.
More negative than 99% of claims this week
The company reported Q2 revenues of $39.01 million, missing analyst estimates.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
The company maintains a precarious balance sheet with under $237 million in cash against $645 million in outstanding debt.
So whatA high debt-to-cash ratio increases insolvency risk and limits the company's ability to fund operations without further dilution or borrowing.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 90% of ticker scores this week
The company missed revenue estimates, lowered future guidance, and reports significant losses and debt.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
3h ago
+24.6%
Price is moving against the score
$1.62 vs $1.30 close before publication (Aug 5) · not market-adjusted
PACB chart →
